- Trial phase
- Preclinical / Development
- Time to market
- Not estimable from available sources. The device has not yet entered clinical trials; the most recent DoD contract (October 2022) was for customized filter design and integration into freeze-dried plasma collection systems.
- Why 3/10
- HemoDefend-BGA is a preclinical/early-stage blood purification filter with no hard, dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The most recent public update was a $4.3M DoD contract awarded in October 2022 for development of a freeze-dried universal plasma filter. No clinical trial start, regulatory submission, or decision date has been announced.
HemoDefend-BGA is an early-stage, government-funded development project with no announced clinical trial start or regulatory submission timeline. Watch for any news of a first-in-human study or a new DoD contract milestone. The stock's primary near-term value drivers are the commercial CytoSorb product and the DrugSorb-ATR FDA de novo submission, not HemoDefend-BGA.
Price Chart
Executive Summary
HemoDefend-BGA is an early-stage blood purification filter being developed by CytoSorbents Corporation (CTSO) with funding from the U.S. Department of Defense. It is designed to remove blood-type antibodies from plasma to create freeze-dried universal plasma for military and civilian trauma use. The program has received cumulative DoD funding of roughly $10M since 2020 across multiple contracts, but no clinical trial has been announced and no regulatory submission date has been set. HemoDefend-BGA is a small, early-stage pipeline program at a company whose primary commercial product is CytoSorb (an approved blood purification filter sold in over 70 countries) and whose main near-term regulatory catalyst is DrugSorb-ATR (which received FDA Breakthrough Device Designation in 2025-2026).
How It Works
HemoDefend-BGA is a filter device that uses proprietary polymer beads to remove blood-type-specific antibodies (anti-A and anti-B) from donated blood plasma. The goal is to convert any blood-type plasma into "universal" plasma that can be given to any patient regardless of blood type, and then freeze-dry it for long-term storage and battlefield use.
Trial Status
HemoDefend-BGA has been funded through multiple U.S. Department of Defense contracts since 2020 (a $2.9M Phase III STTR contract in June 2020, a $1.1M contract in October 2020, a ~$2.0M contract in September 2022, and a ~$4.3M contract in October 2022). These contracts support development of a filter that removes blood-type-specific antibodies from plasma to create freeze-dried universal plasma. No clinical trial records were found in the SecBot biotech pipeline or FDA data tools, and no public update on clinical trial initiation was identified in web searches.
The Two-Sided Case
Upcoming Catalysts
- No hard-dated catalysts identified for HemoDefend-BGA specifically. The broader company catalysts include the DrugSorb-ATR FDA de novo submission status and potential Nasdaq MVLS compliance deadline of December 28, 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Cytosorbents Corp PRESS-RELEASE CTSO ·Originating report